Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
34.91
+0.35 (1.01%)
Jun 18, 2025, 4:00 PM - Market closed
Royalty Pharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover Royalty Pharma stock have a consensus rating of "Strong Buy" and an average price target of $47.33, which forecasts a 35.58% increase in the stock price over the next year. The lowest target is $40 and the highest is $51.
Price Target: $47.33 (+35.58%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 25, 2024.
Analyst Ratings
The average analyst rating for Royalty Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $60 → $40 | Strong Buy | Maintains | $60 → $40 | +14.58% | Oct 25, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $50 → $51 | Strong Buy | Maintains | $50 → $51 | +46.09% | Aug 14, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $48 → $51 | Buy | Maintains | $48 → $51 | +46.09% | Jul 11, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $28 | Strong Buy → Hold | Downgrades | $28 | -19.79% | Jun 3, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +8.85% | Apr 12, 2024 |
Financial Forecast
Revenue This Year
2.93B
from 2.26B
Increased by 29.35%
Revenue Next Year
3.15B
from 2.93B
Increased by 7.58%
EPS This Year
4.48
from 1.91
Increased by 134.48%
EPS Next Year
5.14
from 4.48
Increased by 14.71%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.3B | 3.8B | 4.1B | ||
| Avg | 2.9B | 3.2B | 3.4B | ||
| Low | 2.3B | 2.6B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 43.8% | 28.8% | 31.2% | ||
| Avg | 29.4% | 7.6% | 8.2% | ||
| Low | 2.7% | -12.5% | -19.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.08 | 6.74 | 7.60 | ||
| Avg | 4.48 | 5.14 | 5.73 | ||
| Low | 4.00 | 4.36 | 4.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 165.9% | 50.4% | 47.8% | ||
| Avg | 134.5% | 14.7% | 11.4% | ||
| Low | 109.1% | -2.7% | -10.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.